NASDAQ:NVCR - Novocure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$53.38 +0.17 (+0.32 %)
(As of 02/22/2019 06:53 AM ET)
Previous Close$53.21
Today's Range$52.15 - $53.50
52-Week Range$19.20 - $54.00
Volume1.04 million shs
Average Volume706,382 shs
Market Capitalization$4.96 billion
P/E Ratio-76.26
Dividend YieldN/A
Beta3.25
Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$177.03 million
Book Value$1.27 per share

Profitability

Net Income$-61,660,000.00

Miscellaneous

Employees495
Market Cap$4.96 billion
Next Earnings Date2/28/2019 (Confirmed)
OptionableOptionable

Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings data on Thursday, October, 25th. The medical equipment provider reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The medical equipment provider earned $64.76 million during the quarter, compared to the consensus estimate of $65.61 million. Novocure had a negative return on equity of 52.72% and a negative net margin of 25.37%. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Novocure.

What guidance has Novocure issued on next quarter's earnings?

Novocure updated its fourth quarter 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $69.6-69.6 million, compared to the consensus revenue estimate of $70.47 million.

What price target have analysts set for NVCR?

6 brokers have issued 1 year price targets for Novocure's shares. Their forecasts range from $36.00 to $58.00. On average, they expect Novocure's share price to reach $46.50 in the next twelve months. This suggests that the stock has a possible downside of 12.9%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

What are Wall Street analysts saying about Novocure stock?

Here are some recent quotes from research analysts about Novocure stock:
  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (2/20/2019)
  • 2. Mizuho analysts commented, "We currently model initial revenue for this indication starting in late 2019." (12/6/2018)

Has Novocure been receiving favorable news coverage?

News stories about NVCR stock have been trending positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novocure earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Micron Technology (MU), Alibaba Group (BABA), General Electric (GE), NVIDIA (NVDA), Twitter (TWTR), Celgene (CELG), Synergy Pharmaceuticals (SGYP), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Ultra Clean (UCTT).

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Principal Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Pritesh Shah, Chief Commercial Officer

Who are Novocure's major shareholders?

Novocure's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.16%), Baillie Gifford & Co. (4.84%), Macquarie Group Ltd. (1.32%), Northern Trust Corp (0.84%), Westfield Capital Management Co. LP (0.74%) and Rhenman & Partners Asset Management AB (0.59%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Granite Investment Partners LLC, Nuveen Asset Management LLC, Two Sigma Advisers LP, Castleark Management LLC, Tygh Capital Management Inc., Peregrine Capital Management LLC and First Trust Advisors LP. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Westfield Capital Management Co. LP, Frontier Capital Management Co. LLC, Rhenman & Partners Asset Management AB, Macquarie Group Ltd., SG Americas Securities LLC, Fiera Capital Corp and Cambiar Investors LLC. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $53.38.

How big of a company is Novocure?

Novocure has a market capitalization of $4.96 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Novocure employs 495 workers across the globe.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel